{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:37:16Z","timestamp":1791697036637,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF22OC0074083"],"award-info":[{"award-number":["NNF22OC0074083"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03085-4","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:34:14Z","timestamp":1769250854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Progression to type 2 diabetes among post\u2013myocardial infarction patients with overweight or obesity: a real-world cohort study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-2087","authenticated-orcid":false,"given":"Pernille Tilma","family":"Tonnesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Kris Warnakula","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gyldenkerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene Kaerslund","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"St\u00f8dkilde-J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille Gro","family":"Thrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene H\u00f8jgaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per L\u00f8gstrup","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reimar Wernich","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Toft","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"6","key":"3085_CR1","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s00125-023-05890-y","volume":"66","author":"MB Blond","year":"2023","unstructured":"Blond MB, Faerch K, Herder C, Ziegler D, Stehouwer CDA. The prediabetes conundrum: striking the balance between risk and resources. Diabetologia. 2023;66(6):1016\u201323.","journal-title":"Diabetologia"},{"issue":"11","key":"3085_CR2","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.2337\/dc25-1640","volume":"48","author":"MR Rooney","year":"2025","unstructured":"Rooney MR, He JH, Salpea P, Genitsaridi I, Magliano DJ, Boyko EJ, et al. Global and regional prediabetes prevalence: updates for 2024 and projections for 2050. Diabetes Care. 2025;48(11):e142\u20134.","journal-title":"Diabetes Care"},{"key":"3085_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.athplu.2023.08.002","volume":"54","author":"D Nanavaty","year":"2023","unstructured":"Nanavaty D, Green R, Sanghvi A, Sinha R, Singh S, Mishra T, et al. Prediabetes is an incremental risk factor for adverse cardiac events: a nationwide analysis. Atheroscler Plus. 2023;54:22\u20136.","journal-title":"Atheroscler Plus"},{"issue":"2","key":"3085_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2337\/dc19-1683","volume":"43","author":"C Welsh","year":"2020","unstructured":"Welsh C, Welsh P, Celis-Morales CA, Mark PB, Mackay D, Ghouri N, et al. Glycated hemoglobin, prediabetes, and the links to cardiovascular disease: data from UK biobank. Diabetes Care. 2020;43(2):440\u20135.","journal-title":"Diabetes Care"},{"issue":"9733","key":"3085_CR5","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"C Emerging Risk Factors","year":"2010","unstructured":"Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"issue":"23","key":"3085_CR6","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2024.06.050","volume":"84","author":"C Gyldenkerne","year":"2024","unstructured":"Gyldenkerne C, Kahlert J, Thrane PG, Olesen KKW, Mortensen MB, Sorensen HT, et al. 2-Fold more cardiovascular disease events decades before type 2 diabetes diagnosis: a nationwide registry study. J Am Coll Cardiol. 2024;84(23):2251\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"3085_CR7","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.2337\/dc06-0560","volume":"29","author":"RF Hamman","year":"2006","unstructured":"Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102\u20137.","journal-title":"Diabetes Care"},{"issue":"2","key":"3085_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7326\/0003-4819-133-2-200007180-00008","volume":"133","author":"R Ross","year":"2000","unstructured":"Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med. 2000;133(2):92\u2013103.","journal-title":"Ann Intern Med"},{"issue":"1","key":"3085_CR9","doi-asserted-by":"publisher","first-page":"6032","DOI":"10.1038\/s41598-023-33317-6","volume":"13","author":"MM Brzozowska","year":"2023","unstructured":"Brzozowska MM, Isaacs M, Bliuc D, Baldock PA, Eisman JA, White CP, et al. Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period. Sci Rep. 2023;13(1):6032.","journal-title":"Sci Rep"},{"issue":"12","key":"3085_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-8587(14)70214-1","volume":"2","author":"H Booth","year":"2014","unstructured":"Booth H, Khan O, Prevost T, Reddy M, Dregan A, Charlton J, et al. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol. 2014;2(12):963\u20138.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3085_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"10","key":"3085_CR12","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.2337\/dc21-1785","volume":"45","author":"L Perreault","year":"2022","unstructured":"Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, et al. Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4\u00a0mg among participants with prediabetes in the STEP program. Diabetes Care. 2022;45(10):2396\u2013405.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"3085_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jcpt.13230","volume":"45","author":"S Cornell","year":"2020","unstructured":"Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents. J Clin Pharm Ther. 2020;45(Suppl 1):17\u201327.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"3085_CR14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2337\/dc24-0491","volume":"47","author":"SE Kahn","year":"2024","unstructured":"Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, et al. Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial. Diabetes Care. 2024;47(8):1350\u20139.","journal-title":"Diabetes Care"},{"issue":"24","key":"3085_CR15","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"3085_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"ARG Look","year":"2013","unstructured":"Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145\u201354.","journal-title":"N Engl J Med"},{"issue":"19","key":"3085_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"key":"3085_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2147\/CLEP.S488498","volume":"16","author":"C Gyldenkerne","year":"2024","unstructured":"Gyldenkerne C, Olesen KKW, Thrane PG, Hansen MK, Stodkilde-Jorgensen N, Andersen MH, et al. The Western Denmark heart registry and population-based National health registries. Clin Epidemiol. 2024;16:825\u201336.","journal-title":"Clin Epidemiol"},{"key":"3085_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","volume":"11","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundboll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563\u201391.","journal-title":"Clin Epidemiol"},{"issue":"Suppl 1","key":"3085_CR20","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.2337\/dc24-S003","volume":"47","author":"American Diabetes Association Professional Practice C","year":"2024","unstructured":"American Diabetes Association Professional Practice C. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S43\u201351.","journal-title":"Diabetes Care"},{"issue":"7","key":"3085_CR21","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2337\/dc09-9033","volume":"32","author":"C International Expert","year":"2009","unstructured":"International Expert C. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327\u201334.","journal-title":"Diabetes Care"},{"issue":"13","key":"3085_CR22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/cncr.28695","volume":"120","author":"GW Warren","year":"2014","unstructured":"Warren GW, Alberg AJ, Kraft AS, Cummings KM. The 2014 surgeon general\u2019s report: the health consequences of smoking\u201350 years of progress: a paradigm shift in cancer care. Cancer. 2014;120(13):1914\u20136.","journal-title":"Cancer"},{"issue":"12","key":"3085_CR23","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2337\/dbi25-0025","volume":"74","author":"N Sattar","year":"2025","unstructured":"Sattar N. Atherosclerotic cardiovascular risk before and after type 2 diabetes onset and the roles of ectopic fat and ethnic variation: the 2025 Edwin Bierman award lecture. Diabetes. 2025;74(12):2223\u201330.","journal-title":"Diabetes"},{"issue":"2","key":"3085_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/sim.5922","volume":"33","author":"NA Gouskova","year":"2014","unstructured":"Gouskova NA, Kundu S, Imrey PB, Fine JP. Number needed to treat for time-to-event data with competing risks. Stat Med. 2014;33(2):181\u201392.","journal-title":"Stat Med"},{"issue":"9","key":"3085_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2023.12.029","volume":"83","author":"MK Hansen","year":"2024","unstructured":"Hansen MK, Olesen KKW, Gyldenkerne C, Thrane PG, Stodkilde-Jorgensen N, Mortensen MB, et al. Eligibility for and preventive potential of semaglutide in overweight and obese patients with myocardial infarction. J Am Coll Cardiol. 2024;83(9):956\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"3085_CR26","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc24-0764","volume":"47","author":"I Lingvay","year":"2024","unstructured":"Lingvay I, Deanfield J, Kahn SE, Weeke PE, Toplak H, Scirica BM, et al. Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT. Diabetes Care. 2024;47(8):1360\u20139.","journal-title":"Diabetes Care"},{"key":"3085_CR27","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415.","journal-title":"Eur Heart J"},{"key":"3085_CR28","doi-asserted-by":"publisher","first-page":"133028","DOI":"10.1016\/j.ijcard.2025.133028","volume":"423","author":"V De Sio","year":"2025","unstructured":"De Sio V, Gragnano F, Capolongo A, Guarnaccia N, Maddaluna P, Acerbo V, et al. Eligibility for and practical implications of semaglutide in overweight and obese patients with acute coronary syndrome. Int J Cardiol. 2025;423:133028.","journal-title":"Int J Cardiol"},{"key":"3085_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/ehjqcco\/qcae063","volume":"11","author":"E Zomer","year":"2024","unstructured":"Zomer E, Zhou J, Nelson AJ, Sumithran P, Nanayakkara S, Ball J et al. The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes. Eur Heart J Qual Care Clin Outcomes. 2024;11:857.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"1","key":"3085_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/dci23-0085","volume":"47","author":"ED Parker","year":"2024","unstructured":"Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA, et al. Economic costs of diabetes In the U.S. In 2022. Diabetes Care. 2024;47(1):26\u201343.","journal-title":"Diabetes Care"},{"issue":"6","key":"3085_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"9702","key":"3085_CR32","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","volume":"374","author":"G Research","year":"2009","unstructured":"Diabetes Prevention Program, Research G, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374(9702):1677\u201386.","journal-title":"Lancet"},{"key":"3085_CR33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2024","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2024;392:958.","journal-title":"N Engl J Med"},{"issue":"36","key":"3085_CR34","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"3085_CR35","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association Professional Practice C","year":"2022","unstructured":"American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125\u201343.","journal-title":"Diabetes Care"},{"issue":"16","key":"3085_CR36","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390(16):1455\u201366.","journal-title":"N Engl J Med"},{"issue":"2","key":"3085_CR37","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","volume":"3","author":"S James","year":"2024","unstructured":"James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3(2):EVIDoa2300286.","journal-title":"NEJM Evid"},{"issue":"5","key":"3085_CR38","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1002\/edm2.514","volume":"7","author":"M Ahmed","year":"2024","unstructured":"Ahmed M, Jain H, Javaid H, Ahsan A, Szilagyi S, Ahmad A, et al. Efficacy of sodium-glucose cotransporter-2 inhibitors in patients with acute myocardial infarction: a meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab. 2024;7(5):e514.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"9","key":"3085_CR39","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/oby.24332","volume":"33","author":"CSP Lam","year":"2025","unstructured":"Lam CSP, Rodriguez A, Aminian A, Ferrannini E, Heerspink HJL, Jastreboff AM, et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obes (Silver Spring). 2025;33(9):1645\u201356.","journal-title":"Obes (Silver Spring)"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03085-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:17:43Z","timestamp":1771327063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03085-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3085"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03085-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reported to the Danish Data Protection Agency (record no. 1-16-02-193-18). Patient consent requirements were waived by regional data protection authorities (record no. 14-45-70-24-22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MHA is a minor shareholder in Novo Nordisk and is supported by the Danish Cardiovascular Academy (grant number PhD2023001-HF), which is funded by the Novo Nordisk Foundation, grant number NNF20SA0067242, and the Danish Heart Foundation. KKWO is supported by a research grant from the Danish Cardiovascular Academy funded by the Danish Heart Association and Novo Nordisk.RWT has given single lectures on medical research for pharmaceutical companies (with and without compensation), including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi.NS has consulted for and\/or received speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GlaxoSmithKline, Hanmi Pharmaceuticals, Menarini-Ricerche, Metsera, Novartis, Novo Nordisk, Pfizer, and Roche; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche outside the submitted work. HTS is head of the Department of Clinical Epidemiology, Aarhus University, which receives funding for other studies in the form of institutional research grants to (and administered by) Aarhus University. The Department of Clinical Epidemiology confirms that none of these studies have any relation to the present study. MM is supported by a grant from the Novo Nordisk Foundation (grant number NNF22OC0074083), has received lecture and\/or advisory board fees from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, and Novo Nordisk, has received research grants from Philips, Bayer and Novo Nordisk, has received a travel grant from Novo Nordisk, has ongoing institutional research contracts with Janssen, Novo Nordisk and Philips, and has equity interests in Novo Nordisk, Eli Lilly & Company, and Verve Therapeutics. The remaining authors did not report any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}